Pancreatic cancer research.
The trial, involving 436 patients at over 100 clinical sites in North America, South America, and Europe, is expected to conclude in mid-2005.
Other data show no significant adverse interactions between Virulizin and the current standard of care in pancreatic cancer, gemcitabine. Virulizin stimulates a patient's immune system to attack tumors. In contrast to most standard chemotherapeutic drugs, Virulizin was well tolerated in preliminary research.
|Printer friendly Cite/link Email Feedback|
|Article Type:||Brief Article|
|Date:||Mar 1, 2005|
|Previous Article:||Curry: spice of life.|
|Next Article:||Do you need a low-vision exam?|